Positive predictive value of a case definition for diabetes mellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid study

BMC Medical Research Methodology

Wayne A Ray²  James Daugherty¹  Jackie Mounsey⁵  Mark Olfson³  C Michael Stein⁶  William O Cooper⁴  William V Bobo⁵ 

[1] Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37212, USA;Geriatric Research, Education and Clinical Center, Veterans Administration Tennessee Valley Health Care System, Nashville, TN, 37212, USA;Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA;Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, 37212, USA;Department of Psychiatry, Vanderbilt University School of Medicine, 1500 21st Ave South, Suite 2200 Village at Vanderbilt, Nashville, TN, 37212, USA;Division of Clinical Pharmacology, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37212, USA

关键词: Positive predictive value;    Validity;    Health administrative data;    Computer case definition;    Type 2 diabetes;   

Others  :  1126884
DOI  :  10.1186/1471-2288-12-128

 received in 2012-01-25, accepted in 2012-08-20,  发布年份 2012

【 摘 要 】

Background

We developed and validated an automated database case definition for diabetes in children and youth to facilitate pharmacoepidemiologic investigations of medications and the risk of diabetes.

Methods

The present study was part of an in-progress retrospective cohort study of antipsychotics and diabetes in Tennessee Medicaid enrollees aged 6–24 years. Diabetes was identified from diabetes-related medical care encounters: hospitalizations, outpatient visits, and filled prescriptions. The definition required either a primary inpatient diagnosis or at least two other encounters of different types, most commonly an outpatient diagnosis with a prescription. Type 1 diabetes was defined by insulin prescriptions with at most one oral hypoglycemic prescription; other cases were considered type 2 diabetes. The definition was validated for cohort members in the 15 county region geographically proximate to the investigators. Medical records were reviewed and adjudicated for cases that met the automated database definition as well as for a sample of persons with other diabetes-related medical care encounters.

Results

The study included 64 cases that met the automated database definition. Records were adjudicated for 46 (71.9%), of which 41 (89.1%) met clinical criteria for newly diagnosed diabetes. The positive predictive value for type 1 diabetes was 80.0%. For type 2 and unspecified diabetes combined, the positive predictive value was 83.9%. The estimated sensitivity of the definition, based on adjudication for a sample of 30 cases not meeting the automated database definition, was 64.8%.

Conclusion

These results suggest that the automated database case definition for diabetes may be useful for pharmacoepidemiologic studies of medications and diabetes.

【 授权许可】

   
2012 Bobo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, Beckles GL, Saaddine J, Gregg EW, Williamson DF, Narayan KM: Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000, 136(5):664-672.
• [2]Pinhas-Hamiel O, Zeitler P: The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005, 146(5):693-700.
• [3]Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al.: Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010, 42(7):579-589.
• [4]Herder C, Roden M: Genetics of type 2 diabetes: pathophysiologic and clinical relevance. Eur J Clin Invest 2011, 41(6):679-692.
• [5]Nettleton JA, McKeown NM, Kanoni S, Lamaitre RN, Hivert MF, et al.: Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. Diabetes Care 2010, 33(12):2684-2691.
• [6]Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345(11):790-797.
• [7]Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Benditti E, Nathan DM: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374(9702):1677-1686.
• [8]Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Kjunti K: Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007, 334(7588):299.
• [9]Hectors TL, Vanparys C, van der Ven K, Martens GA, Jorens PG, van Gaal LF, Covaci A, De Coen W, Blust R: Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia 2011, 54(6):1273-1290.
• [10]Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
• [11]McIntyre RS, Jerrell JM: Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 2008, 162(10):929-935.
• [12]Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006, 45(7):771-791.
• [13]Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287(19):2570-2581.
• [14]Bowden DW, Cox AJ, Freedman BI, Hugenschimdt CE, Wagenknecht LE, Herrington D, Agarwal S, Register TD, Maldjian JA, Ng MC, Hsu FC, Langefeld CD, Williamson JD, Carr JJ: Review of the Diabetes Heart Study (DHS) family of studies: a comprehensively examined sample for genetic and epidemiological studies of type 2 diabetes and its complications. Rev Diabet Stud 2010, 7(3):188-201.
• [15]Pinhas-Hamiel O, Zeitler P: Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007, 369(9575):1823-1831.
• [16]Ray WA: Population-based studies of adverse drug effects. N Engl J Med 2003, 349(17):1592-1594.
• [17]Ray WA: Improving automated database studies. Epidemiology 2011, 22(3):302-304.
• [18]Ray WA, Griffin MR: Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989, 129(4):837-849.
• [19]Geller DH, Pacaud D, Gordon CM, Misra M: The use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol 2011, 11:9.
• [20]American Diabetes Association: Standards of medical care in diabetes--2011. Diabetes Care 2011, 34(Suppl 1):S11-S61.
• [21]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62-S69.
• [22]Haynes RB, Sackett DL, Guyatt GH, Tigwell P: Clinical Epidemiology. 3rd edition. New York: Lippincott Williams & Wilkins; 2006.
• [23]Dabelea D, DeGroat J, Sorrelman C, Glass M, Percy CA, Avery C, Hu D, D’Agostino RB, Beyer J, Imperatore G, Testaverde L, Klingensmith G, Hamman RF: Diabetes in Navajo youth. Diabetes Care 2009, 32(Suppl 2):S141-S137.
• [24]Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002, 19(9):708-723.
• [25]Colagiuri S: Epidemiology of prediabetes. Med Clin North Am 2011, 95(2):299-307.
• [26]Coccurello R, Moles A: Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010, 127(3):210-251.
• [27]Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K: Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006, 164(7):672-681.
• [28]Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S: Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 305(24):2525-2531.
• [29]Miller DR, Safford MM, Pogach LM: Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 2004, 27(Suppl 2):B10-B21.
• [30]Bloomgarden ZT: Type 2 diabetes in the young: the evolving epidemic. Diabetes Care 2004, 27(4):998-1010.
• [31]Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ: ISPAD Clinical Practice Consensus Guidelines 2006–2007: Type 2 diabetes mellitus in the child and adolescent. Pediatric Diabetes 2008, 9(5):512-526.
• [32]Dart A, Martens PJ, Sellers EA, Brownell MD, Rigatto C, Dean HJ: Validation of a pediatric diabetes case definition using administrative health data in Manitoba, Canada. Diabetes Care 2011, 34(4):898-903.
• [33]Rhodes ET, Laffel LM, Gonzalez TV, Ludwig DS: Accuracy of administrative coding for type 2 diabetes in children, adolescents, and young adults. Diabetes Care 2007, 30(1):141-143.
• [34]Hsia Y, Neubert AC, Rani F, Viner RM, Hindmarsh PC, Wong IC: An increase in the prevalence of type 1 and 2 diabetes in children and adolescents: results from prescription data from a UK general practice database. Br J Clin Pharmacol 2009, 67(2):242-249.
• [35]Rosenbloom AL: Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations. Paediatric Drugs 2002, 4(4):209-221.
• [36]Li H, Isomaa B, Taskinen MR, Groop L, Tuomi T: Consequences of a family history of type 1 and type 2 diabetes on the phenotype of patients with type 2 diabetes. Diabetes Care 2000, 23(5):589-594.
• [37]Bruno G, Runzo C, Cavallo-Perin P, Merletti F, Rivetti M, Pinach S, Novelli G, Trovati M, Cerutti F, Pagano G: Piedmont Study Group for Diabetes Epidemiology: Incidence of type 1 and type 2 diabetes in adults aged 30–49 years: the population-based registry in the province of Turin, Italy. Diabetes Care 2005, 28(11):2613-2619.